Here's Where Oracle Is Worth a Shot

In a market filled with charts without a clear stop, ORCL offers that.

Cerner Finally Reaches Our Price Target From Long Ago

Oracle's acquisition bid today for CERN of about $28.3B certainly helped us get there.

Zoetis Stock Has More Room to Run

ZTS is in a longer-term uptrend that should continue when the weakness in the broader market subsides.

Novavax Rallies and Turns the Charts More Positive

I like the risk/reward set up now.

Asian Markets Sink in Synchronicity to Test One-Year Lows

With Chinese tech stocks selling off and inflation worrying even the Bank of Japan, there are multiple Asia-specific reasons for the decline.

CVS Health Nears Our Longer-Term Price Target

We now have two new price targets.

Eyeing Bausch Health? The Stock Needs Some Primary Care

Let's check out the charts of this name that will be splitting into three companies.

Let's Check Up on 2 Immunology-Focused Oncology ETFs

Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.

UnitedHealth Group's Charts Continue to Point Higher

Here's our next price target.

Here's My Risk and Reward Parameters for Vir Biotechnology

Let's look over the charts and indicators.